Bpifrance awarded Exeliom Biosciences with a 1.8M€ grant to accelerate the development of its lead candidate EXL01, a Live Biotherapeutics Products (LBP) to fight Crohn's Disease.

This support from Bpifrance will help Exeliom Biosciences tackle the two main challenges ahead: 1) building a regulatory dossier for EXL01 to secure a first clinical trial authorization in an emerging regulatory category, and 2) scaling-up the manufacturing process to clinical-scale.